Skip to main
ASMB

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences Inc. is advancing its hepatitis B virus (HBV) cure program, which has the potential to significantly improve the current low cure rates through the development of novel small molecule therapeutics aimed at multiple steps of the HBV lifecycle. The company's progress includes promising clinical data supporting the robustness of its drug candidates, including ABI-5366, which has demonstrated substantial antiviral activity and the possibility for future lifecycle expansion. Furthermore, a recent $175 million equity financing is expected to fund Assembly Biosciences through 2027, underpinning its optimistic financial outlook and potential for substantial revenue generation from its innovative HBV therapies.

Bears say

Assembly Biosciences Inc. is facing significant challenges in advancing its HBV-cure program, as negative outcomes from its clinical trials, particularly for the ABI-6250 and ABI-1179/5366 candidates, raise concerns about their future in the clinic. The company's financial health is further undermined by a persistent history of losses, emphasizing the lack of a proven track record of profitability. Additionally, adverse safety signals, poor efficacy results, and limited virologic responses in clinical trial participants may hinder investor confidence and impact future revenue generation.

Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.

According to 4 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.